^
    Back
    Association details:
    Biomarker:HER-2 positive
    Cancer:Gastric Cancer
    Drug:AiRuiKa (camrelizumab) (PD1 inhibitor) +
    Irene (pyrotinib) (EGFR inhibitor, HER2 inhibitor, HER4 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrialsregister.eu
    Title:

    A Prospective, Single-Arm, Phase II Study of Camrelizumab Combined with Pyrotinib Maleate, Nab-Paclitaxel and Tegafur Chemotherapy in First-Line Treatment of HER2-Positive Gastric Cancer

    Excerpt:
    ...Locally advanced unresectable or metastatic HER2-positive adenocarcinoma of the stomach or gastroesophageal junction confirmed by histology or cytology; 3. ...
    Trial ID:
    ChiCTR2100051618
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrialsregister.eu
    Title:

    An open-label, dose-escalation, and extension study of Camrelizumab combined with pyrotinib maleate and CapeOX in first-line treatment of HER2-positive gastric cancer

    Excerpt:
    ...Histological or cytologically confirmed diagnosis of previously untreated locally advanced unresectable or metastatic HER2 positive gastric or gastroesophageal junction adenocarcinoma3. ...
    Trial ID:
    ChiCTR2000029717
    Less C2 evidence
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    EClinicalMedicine
    Title:

    Multicenter phase I dose escalation and expansion study of pyrotinib in combination with camrelizumab and chemotherapy as first-line treatment for HER2-positive advanced gastric and gastroesophageal junction adenocarcinoma

    Published date:
    11/20/2023
    Excerpt:
    Pyrotinib plus camrelizumab and chemotherapy showed promising efficacy in the first-line treatment of advanced HER2-positive G/GEJ cancer. The safety profile was consistent with known toxicities of the agents, and no new or unexpected safety signals were identified.
    Secondary therapy:
    Chemotherapy
    DOI:
    10.1016/j.eclinm.2023.102314
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO-GI 2023
    Title:

    First-line of camrelizumab plus pyrotinib and chemotherapy in HER2-positive advanced gastric or gastroesophageal junction adenocarcinoma: A dose escalation and expansion phase I study.

    Published date:
    01/17/2023
    Excerpt:
    The objective response rate and disease control rate were 96.0% and 100%, respectively. The 12-month progression-free survival rate and overall survival rate were 77.1% and 89.3%, respectively….Camrelizumab plus pyrotinib and chemotherapy showed promising efficacy in the first-line treatment of HER2-positive G/GEJ cancer, with acceptable safety profiles.
    Secondary therapy:
    Chemotherapy
    DOI:
    10.1200/JCO.2023.41.3_suppl.356